Hi there, A few hours ago, you requested to receive a free copy of MarketBeat's latest report, " The Best Nuclear Energy Stocks to Buy." I noticed that you hadn't opened the email we sent with your free report, so I just wanted to follow up and make sure you received it. If you missed the initial message, you can access your free report directly by clicking the link below: Download your report here (PDF). If you have any trouble accessing the report, please don't hesitate to reach out to our support team by replying to this message. Thanks, Jessica Mitacek
Managing Editor
MarketBeat
Just For You
3 Longevity ETFs to Buy and Hold (and Hold)Author: Nathan Reiff. Article Posted: 6/8/2026. 
Key Points
- The longevity industry is expected to nearly triple in size from 2025 to 2035, creating growing interest from investors seeking exposure through ETFs.
- XBI, BMED, and AGNG offer varying degrees of longevity-focused exposure, with trade-offs across diversification, expense ratios, liquidity, and active versus passive management.
- AGNG provides the most direct longevity investment theme but carries notable drawbacks, including only $81 million in assets and low trading volumes.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Longevity is increasingly becoming a big business. Advances in healthcare technology and AI have prompted both prominent medical professionals and individual investors to imagine a future in which people live longer, healthier lives. Though still fairly small overall, the longevity industry is expected to nearly triple in size from 2025 to 2035. Longevity remains very much a niche play for investors, and there are few ways to get involved directly outside of positions in a handful of individual biotech firms. Investors taking a longer view of the industry—or those unsure how to make a specific bet on one or more individual companies, given the nascent nature of the longevity space—might instead opt for an exchange-traded fund (ETF).
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776.
From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society.
His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. Watch Porter Stansberry's full briefing and learn how to prepare now
The ETFs below provide varying degrees of specificity with regard to longevity companies, ranging from the broadest to the narrowest. XBI: Broad Biotech ApproachThe SPDR S&P Biotech ETF (NYSEARCA: XBI) is a general biotech ETF with a basket of close to 150 different U.S. biotech companies across the market capitalization spectrum. The fund is popular among investors, with about $8 billion in assets under management and a one-month average trading volume of close to 8.5 million. Biotech companies tend to carry a fair amount of risk, given that most firms in this space are working to develop commercially viable products. As such, the bulk of XBI's portfolio consists of smaller firms in the mid-cap and small-cap ranges. It also weights its positions fairly equally, ensuring that no single holding represents more than about 1.8% of the portfolio. This may help distribute risk, although it might also prevent XBI from benefiting as much from major rallies in individual names. XBI is not exactly a longevity-focused fund, but all the companies in this basket operate in the healthcare space and are developing new therapies and products to cure or address various diseases. Its return of about 5.5% year-to-date (YTD) is somewhat sluggish compared to the broader market. However, over the last 12 months, the fund has performed much better, delivering more than 50% in returns. A modest dividend yield of 0.34% also helps justify the 0.35% expense ratio. BMED: Health Innovation for Cutting Edge TechnologyTaking an active approach, the iShares Health Innovation Active ETF (NYSEARCA: BMED) does not track an index, but instead seeks to compile a manager-selected list of innovative companies from across the healthcare sector. As an actively managed fund, investors can expect BMED to carry a higher annual fee, and in this case, the expense ratio is 0.55%. BMED's portfolio is quite narrow compared to XBI, with roughly 50 positions of varying sizes. The largest holdings in the fund's basket each account for more than 5%, so this ETF is not nearly as diversified as many other offerings in the space. BMED is also not specifically linked to the longevity industry, although it does include a number of biotech names and other companies focused on this area. So far in 2026, BMED's managers have significantly underperformed the market. Fortunately, as an actively managed fund, this ETF is not subject to quarterly rebalancings and can instead modify its portfolio at any time. AGNG: Focused on Enhancing and Elongating the Lives of SeniorsThe Global X Aging Population ETF (NASDAQ: AGNG) is perhaps the best ETF for a singular focus on longevity. Taking a market-cap-weighted approach to portfolio construction, this fund tracks an index of companies aiming to enhance and elongate the lives of senior citizens. This results in a basket of about 90 companies in the medical device, life sciences, biotech, and pharmaceutical industries, with a broader geographic focus on developed markets. One trade-off for the specificity of AGNG's theme is a smaller asset base: the fund has $81 million in managed assets and similarly low trading volumes, so liquidity is a factor investors should keep in mind. It also carries a higher expense ratio than some investors may be comfortable with, at 0.50%. Like BMED, the strategy has not yet paid off in 2026 returns, so investors might prefer to think of AGNG as a long-term bet on the industry. Its dividend payment does help sweeten the offer, although the yield of 0.89% is likely not enough to make investors consider AGNG a dividend play per se. |
0 Response to "Don't forget your free report!"
Post a Comment